ImmuneRegen BioSciences, Inc. (IRBO) Confirms Homspera(R) Advances Wound Healing in Topical Application
8/13/2008 8:57:54 AM
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--ImmuneRegen® BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), today announced that in a controlled study performed on Yorkshire pigs, its wound-healing drug candidate, Homspera®, has accelerated the healing process of deep, dermal excisions. ImmuneRegen performed the in vivo study with Bio-Quant, Inc., a biotechnology development company that also provides contracted preclinical research services. The study results add to the body of evidence of Homspera’s ability to stimulate wound healing and further support the potential application of Homspera in diverse areas such as thermal and chemical burns, battlefield trauma, and wounds such as diabetic and pressure ulcers, as well as surgical and traumatic wounds.
comments powered by